

		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00
Kyoto International Conference Center (KICC)	No.1 (1F Main Hall)			JSH-ASH Joint Symposium Recent advances in lymphoma biology and treatment development Chairs : Koji Izutsu, Robert S. Negrin		Special Lecture 1	LS1-1 CHUGAI PHARMACEUTICAL CO., LTD.	Opening/Award Ceremony	Presidential Lecture	Presidential Symposium 1 Germline predisposition to somatic evolution Chair : Seishi Ogawa	ES1-1 Johnson & Johnson		JSH Business Meeting
	No.2 (2F Room A)			Symposium 1 Acute leukemia, recent advances in elucidating the genetic, epigenetic and molecular pathogenesis Chairs : Yasuhito Nannya, Hiroki Yamaguchi			LS1-2 Gilead Sciences K.K.			Clinical Debate 1	ES1-2 PharmaEssentia Japan KK		
	No.3 (2F Room B-1)			EL1-3-1	EL1-3-2	EL1-3-3	LS1-3 Bristol Myers Squibb K.K.			Patient and Public Involvement Symposium Connecting patient voices to society and international networks— patient organisation collaboration, PPI, and global perspectives Chairs : Ayako Arai, Kota Ohashi	ES1-3 AbbVie GK		
	No.4 (2F Room B-2)			EL1-4-1	EL1-4-2	EL1-4-3	LS1-4 Takeda Pharmaceutical Company Limited				ES1-4 Pfizer Japan Inc. Medical Affairs		
	No.5 (1F Sakura)			EL1-5-1	EL1-5-2	EL1-5-3	LS1-5 ASAHI KASEI THERAPEUTICS CORPORATION			EL1-4-4	EL1-4-5	EL1-4-6	ES1-5 Novartis Pharma K.K.
	No.6 (1F Room C-1)			SETP1 Clinical Challenge for Leukemia		SETP2 Genomic Analysis for Hematologic Malignancy	LS1-6 CSL Behring K.K.			O1-6C	O1-6D	ES1-6 Japan Medical Office, Takeda Pharmaceutical Company Limited.	
	No.7 (1F Room C-2)			O1-7A B-cell Lymphoma: Basic Research 1 Chair : Ai Kotani	O1-7B		LS1-7 Meiji Seika Pharma Co., Ltd.			O1-7C Aggressive B-cell Lymphoma: Cellular Immunotherapy 1 Chair : Shinichi Makita	O1-7D	ES1-7 BeOne Medicines Japan	
	No.8 (1F Room D)			O1-8A AML: Clinical 1 Chair : Ken Ishiyama	O1-8B		LS1-8 argenx Japan K.K.			O1-8C T/NK, HL, Other: Rare Hematological Disorders Chair : Makoto Yoshimitsu	O1-8D T/NK, HL, Other: Clinical Research of cHL and ENKL Chair : Shigeru Kusumoto	ES1-8 Sanofi K.K.	
	No.9 (1F Room E)			O1-9A	O1-9B ALL: Clinical 2 Chair : Yuho Najima		LS1-9 Shionogi & Co., Ltd.			O1-9C	O1-9D	ES1-9 GlaxoSmithKline K.K.	
	No.10 (1F Room F)			O1-10A MPN: Clinical 1 Chair : Yoko Edahiro	O1-10B		LS1-10 Therakos Japan			O1-10C MPN: Basic 1 Chair : Kazuhiko Ikeda	O1-10D	ES1-10 Asahi Kasei Therapeutics Corporation	
	No.11 (1F Room G)			O1-11A MDS: Basic Research 1 Chair : Katsuto Takenaka	O1-11B					O1-11C MDS: Clinical Chair : Hidehiro Itonaga	O1-11D		
	No.12 (1F Room H)			O1-12A	O1-12B		LS1-12 DAIICHI SANKYO COMPANY, LIMITED.			O1-12C	O1-12D	ES1-12 ONO PHARMACEUTICAL CO., LTD.	
	No.13 (2F Room I)			O1-13A	O1-13B		LS1-13 Medical Affairs Department, Novo Nordisk Pharma Ltd.			O1-13C	O1-13D	ES1-13 Novo Nordisk Pharma Ltd.	
The Prince Kyoto Takaragaike	No.14 (2F Room J)			O1-14A RBC: Basic Chair : Hiroki Kato	O1-14B					O1-14C Hematopoietic Microenvironment 1 Chair : Yoshihiro Hayashi	O1-14D	ES1-14 Kyowa Kirin Co., Ltd.	
	No.15 (2F Room K)			O1-15A Immunology/Cell/Gene 1 Chair : Fumio Nakahara	O1-15B		LS1-15 Sobi Japan			O1-15C CAR T Cell Therapy: Basic 1 Chair : Haruko Tashiro	O1-15D	ES1-15 CSL Behring K.K. Medical Affairs	
	No.16 (1F Royal Room)			O1-16A	O1-16B		LS1-16 Sumitomo Pharma Co., Ltd.			O1-16C	O1-16D	ES1-16 CHUGAI PHARMACEUTICAL CO., LTD.	
	No.17 (B1F Rose Room)			O1-17A Multiple Myeloma: Basic Research Chair : Hiroto Ohguchi	O1-17B		LS1-17 Alexion Pharma GK			O1-17C AML: Basic 1 Chair : Akihiko Yokoyama	O1-17D AML: Basic 2 Chair : Daiki Karigane	ES1-17 Meiji Seika Pharma Co., Ltd.	
	No.18 (B2F Gold Room)			Symposium 2 Artificial intelligence-assisted acceleration of hematopoiesis research Chairs : Keiyo Takubo, Satoshi Yamazaki			LS1-18 Medical Affairs Division, Johnson & Johnson			O1-18C AML: Clinical 3 Chair : Masao Ogata	O1-18D	ES1-18 Bristol Myers Squibb K.K.	
Poster (KICC 1F Annex Hall / The Prince Kyoto Takaragaike B2F Prince Hall)				Poster Mounting (9 : 00~11 : 00)				Poster Viewing (11 : 00~17 : 35)				Poster Discussion (17 : 35~18 : 25)	
		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00

		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	
Kyoto International Conference Center (KICC)	No.1 (1F Main Hall)	MS2-1 Novartis Pharma K.K. Medical Affairs	Symposium 3 Pioneers and game changers: new horizons in leukemia Chairs : Mariko Eguchi, Itaru Kato			ASH Special Lecture	LS2-1 AbbVie GK	Plenary Session Chairs : Kazuya Shimoda, Toshihiro Miyamoto	Special Lecture 2 Chair : Seishi Ogawa Speaker : John E. Dick	Presidential Symposium 2 Next-generation insights into myeloid neoplasms Chair : Seishi Ogawa			ES2-1 Sanofi K.K.	
	No.2 (2F Room A)	MS2-2 Johnson & Johnson	Women Physicians Career Symposium Empowering women in hematology: where we stand globally and in Japan Chairs : Miki Ando, Mamiko Sakata-Yanagimoto			IS2-2 Genmab KK, Medical Affairs / AbbVie GK, Medical	LS2-2 Johnson & Johnson			Symposium 5 Minimal residual disease and post-transplant maintenance therapy Chairs : Shinichi Kako, Ken-ichi Matsuoka			ES2-2 Alexion Pharma G.K.	
	No.3 (2F Room B-1)	MS2-3 CHUGAI PHARMACEUTICAL CO., LTD.	EL2-3-1	EL2-3-2	EL2-3-3	IS2-3 Recordati Rare Diseases Japan K.K.	LS2-3 Sanofi K.K.		EL2-3-4	EL2-3-5	EL2-3-6	ES2-3 Johnson & Johnson	Reception for all the participants 1F, Swan & Garden Kyoto International Conference Center (19 : 15~)	
	No.4 (2F Room B-2)	MS2-4 Gilead Sciences K.K.	EL2-4-1	EL2-4-2	EL2-4-3			Chair : Akifumi Takaori-Kondo Speaker : Robert S. Negrin	LS2-4 Recordati Rare Diseases Japan K.K.	EL2-4-4	EL2-4-5	EL2-4-6		ES2-4 Novartis Pharma K.K.
	No.5 (1F Sakura)	MS2-5 Sanofi K.K.	EL2-5-1	EL2-5-2	EL2-5-3	LS2-5 Novartis Pharma K.K.	EL2-5-4	EL2-5-5	EL2-5-6	ES2-5 Otsuka Pharmaceutical Co., Ltd.				
	No.6 (1F Room C-1)	MS2-6 Takeda Pharmaceutical Company Limited	SETP3 Stem Cell Biology		SETP4 Lymphoma		LS2-6 AstraZeneca K.K.	O2-6C DLBCL: Clinical Trial 1 Chair : Nobuhiko Nakamura		O2-6D		ES2-6 AbbVie GK		
	No.7 (1F Room C-2)	MS2-7 BeOne Medicines Japan	O2-7A Aggressive B-cell Lymphoma: CNS 1 Chair : Eisei Kondo		O2-7B		LS2-7 Pfizer Japan Inc.	O2-7C Aggressive B-cell Lymphoma: Prognostic Factors Chair : Masatoshi Sakurai		O2-7D		ES2-7 Takeda Pharmaceutical Company Limited		
	No.8 (1F Room D)	MS2-8 ONO PHARMACEUTICAL CO., LTD.	O2-8A CML: Translational Research Chair : Tomoiku Takaku		O2-8B		LS2-8 Amgen K.K./ Astellas Pharma Inc.	JSH-EHA Travel Grant Awardee's Session in JSH2026 Chairs : Naoki Hosen, Konstanze Döhner				ES2-8 Gilead Sciences K.K.		
	No.9 (1F Room E)	MS2-9 GlaxoSmithKline K.K.	O2-9A		O2-9B AML: Basic 4 Chair : Keita Yamamoto			LS2-9 Nippon Shinyaku Co., Ltd.	O2-9C		O2-9D AML: Translational 2 Chair : Kazuaki Yokoyama		ES2-9 CHUGAI PHARMACEUTICAL CO., LTD.	
	No.10 (1F Room F)	MS2-10 Novo Nordisk Pharma Ltd.	O2-10A		O2-10B		LS2-10 SRL, Inc./ H.U. Frontier, Inc.	O2-10C		O2-10D Anemia 2 Chair : Yoshitaka Zaimoku		ES2-10 Nippon Shinyaku Co., Ltd.		
	No.11 (1F Room G)		O2-11A		O2-11B Thrombosis and Hemostasis Chair : Seiji Madoiwa			O2-11C		O2-11D				
	No.12 (1F Room H)	MS2-12 ASAHI KASEI THERAPEUTICS CORPORATION	O2-12A HCT: Engraftment/ GVHD Chair : Ken Ohmine		O2-12B Transplant Outcomes 3 Chair : Hideaki Fujiwara		LS2-12 Minophagen Pharmaceutical Co., Ltd.	O2-12C		O2-12D		ES2-12 Sumitomo Pharma Co., Ltd.		
	No.13 (2F Room I)	MS2-13 DAIICHI SANKYO COMPANY, LIMITED.	O2-13A		O2-13B		LS2-13 Eisai Japan	O2-13C		O2-13D		ES2-13 Takeda Pharmaceutical Company Limited, Japan Medical Office		
	No.14 (2F Room J)	MS2-14 CSL Behring K.K.	O2-14A Immunotherapy: Basic 1 Chair : Yusuke Ito		O2-14B		LS2-14 Sumitomo Pharma Co., Ltd.	O2-14C Hematopoietic Regulation 1 Chair : Maiko Sezaki		O2-14D		ES2-14 AstraZeneca K.K.		
	No.15 (2F Room K)	MS2-15 Sumitomo Pharma Co., Ltd.	O2-15A		O2-15B Infections, Others Chair : Takehiko Mori		LS2-15 KM Biologics Co.,Ltd./ Japan Blood Products Organization	O2-15C Hematology Practice 1 Chair : Masahiro Sekiguchi		O2-15D		ES2-15 Sobi Japan/ Asahi Kasei Therapeutics Corporation		
The Prince Kyoto Takaragaike	No.16 (1F Royal Room)	MS2-16 Astellas Pharma Inc. Medical Affairs	O2-16A		O2-16B		LS2-16 Takeda Pharmaceutical Company Limited	O2-16C		O2-16D		ES2-16 Bristol Myers Squibb K.K.		
	No.17 (B1F Rose Room)	MS2-17 Nippon Shinyaku Co., Ltd.	O2-17A		O2-17B		LS2-17 BeOne Medicines Japan	O2-17C Chronic Lymphocytic Leukemia Chair : Kensuke Kojima		O2-17D		ES2-17 CHUGAI PHARMACEUTICAL CO., LTD.		
	No.18 (B2F Gold Room)	MS2-18 Genmab KK, Medical Affairs / AbbVie GK, Medical	Symposium 4 Recent insights in molecular pathogenesis of bone marrow failure Chairs : Tohru Fujiwara, Hirohito Yamazaki				LS2-18 ONO PHARMACEUTICAL CO., LTD.	Symposium 6 Personalized treatment for multiple myeloma Chairs : Emiko Sakaida, Satoshi Yoshihara				ES2-18 Pfizer Japan Inc.		
Poster (KICC 1F Annex Hall / The Prince Kyoto Takaragaike B2F Prince Hall)				Poster Mounting (9 : 00~11 : 00)		Poster Viewing (11 : 00~18 : 00)							Poster Discussion (18 : 00~18 : 50)	
		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	

		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	
Kyoto International Conference Center (KICC)	No.1 (1F Main Hall)	MS3-1 GlaxoSmithKline K.K.	JSH-EHA Joint Symposium Advances in research and treatment of MDS Chairs : Hideki Makishima, Konstanze Döhner			EHA Special Lecture	LS3-1 PharmaEssentia Japan KK	JSH Award Lecture	Special Symposium			Closing Ceremony		
	No.2 (2F Room A)	MS3-2 Incyte Biosciences Japan G.K.	Clinical Debate 2			IS3-2 Alexion Pharma G.K. Medical Affairs Division	LS3-2 CHUGAI PHARMACEUTICAL CO., LTD.	Keynote Lecture	Symposium 8 Cutting edge of CAR T cell research Chairs : Miki Ando, Toshiki Ochi					
	No.3 (2F Room B-1)	MS3-3 Medical Affairs Division, Johnson & Johnson	EL3-3-1	EL3-3-2	EL3-3-3	IS3-3 Recordati Rare Diseases Japan K.K.	LS3-3 GlaxoSmithKline K.K.		Public Symposium					
	No.4 (2F Room B-2)	MS3-4 PharmaEssentia Japan KK	EL3-4-1	EL3-4-2	EL3-4-3	Chair : Mamiko Sakata-Yanagimoto Speaker : Konstanze Döhner			LS3-4 Astellas Pharma Inc.	Chair : Yasushi Miyazaki Speaker : Esther Natalie Oliva		EL3-4-4	EL3-4-5	EL3-4-6 Chair : Hitoshi Kiyoi Speaker : Daniel Pollyea
	No.5 (1F Sakura)	MS3-5 CHUGAI PHARMACEUTICAL CO., LTD./ Nippon Shinyaku Co.,Ltd.	EL3-5-1	EL3-5-2	EL3-5-3		LS3-5 Genmab K.K./ AbbVie GK			EL3-5-4	EL3-5-5	EL3-5-6		
	No.6 (1F Room C-1)	MS3-6 ONO PHARMACEUTICAL CO., LTD.	O3-6A	O3-6B Aggressive B-cell Lymphoma: CNS 2 Chair : Yuko Shirouchi		LS3-6 KISSEI PHARMACEUTICAL CO.,LTD.				O3-6C	O3-6D			
	No.7 (1F Room C-2)	MS3-7 Pfizer Japan Inc. Oncology Medical Affairs	O3-7A Aggressive B-cell Lymphoma: Clinical Research 2 Chair : Sayako Yuda	O3-7B		LS3-7 Incyte Biosciences Japan G.K.				O3-7C	O3-7D			
	No.8 (1F Room D)	MS3-8 Novartis Pharma K.K.	Asian Joint Panel Discussion Hematologic malignancies in adolescents and young adults Chairs : Fumihiko Hayakawa, Yu Hu			LS3-8 Otsuka Pharmaceutical Co., Ltd.				O3-8C CML: Clinical Trial Chair : Noriyoshi Iriyama	O3-8D			
	No.9 (1F Room E)	MS3-9 Recordati Rare Diseases Japan K.K	O3-9A	O3-9B		LS3-9 Sobi Japan/ Asahi Kasei Therapeutics Corporation				O3-9C AML: Translational 3 Chair : Masahiro Onozawa	O3-9D			
	No.10 (1F Room F)	MS3-10 Takeda Pharmaceutical Company Limited	O3-10A	O3-10B		LS3-10 Fuji Pharma Co.,Ltd.				O3-10C	O3-10D			
	No.11 (1F Room G)		O3-11A	O3-11B						O3-11C VWF and Hemophiliacs Chair : Azusa Nagao	O3-11D			
	No.12 (1F Room H)	MS3-12 Asahi Kasei Therapeutics Corporation	O3-12A	O3-12B PNH 2 Chair : Takahiro Suzuki		LS3-12 Japan Medical Office, Takeda Pharmaceutical Company Limited				O3-12C	O3-12D Anemia 4 Chair : Fumi Nakamura			
	No.13 (2F Room I)	MS3-13 Gilead Sciences K.K.	O3-13A	O3-13B ALL: Translational Chair : Koji Nagafuji		LS3-13 INVIVOSCRIBE / LabPMM				O3-13C ALL: Basic 1 Chair : Daisuke Hasegawa	O3-13D			
	No.14 (2F Room J)		O3-14A	O3-14B Indolent Lymphoma: Clinical Trial 2 Chair : Shinya Rai						O3-14C	O3-14D			
	No.15 (2F Room K)	MS3-15 Daiichi Sankyo Medical Affairs	O3-15A	O3-15B		LS3-15 OHARA Pharmaceutical Co., Ltd.				O3-15C	O3-15D			
The Prince Kyoto Takaragaike	No.16 (1F Royal Room)	MS3-16 Johnson & Johnson	O3-16A Multiple Myeloma: Prospective Clinical Trial Chair : Junya Kuroda	O3-16B Multiple Myeloma: Clinical Research Chair : Daisuke Ogiya		LS3-16 Nihon Servier Co., Ltd.				O3-16C	O3-16D			
	No.17 (B1F Rose Room)	MS3-17 Bristol Myers Squibb K.K.	O3-17A	O3-17B		LS3-17 Kyowa Kirin Co., Ltd.				O3-17C	O3-17D			
	No.18 (B2F Gold Room)	MS3-18 Sanofi K.K.	Symposium 7 Bleeding disorder of unknown cause (BDUC) Chairs : Nobuaki Suzuki, Keiji Nogami			LS3-18 MSD K.K.				O3-18C	O3-18D Indolent Lymphoma: Clinical3 Chair : Masuho Saburi			
Poster (KICC 1F Annex Hall / The Prince Kyoto Takaragaike B2F Prince Hall)		Poster Mounting (9 : 00~11 : 00)			Poster Viewing (11 : 00~13 : 30)			Poster Discussion (13 : 30~14 : 20)						
		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	